We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NxStage Medical: NxGen Hemodialysis System Now CE Marked
Read MoreHide Full Article
NxStage Medical, Inc. recently announced the receipt of CE mark for its NxGen Hemodialysis System, an innovative device with easier user interface and integrated blood pressure monitor system for patients performing home hemodialysis. This approval is expected to strengthen the company’s foothold in the growing hemodialysis care market in Europe.
Notably, NxGen leverages on the company’s flagship NxStage System One, the first and only portable hemodialysis system, which has been cleared by the US FDA for home hemodialysis and home nocturnal hemodialysis. However, NxGen is currently under the review for a 510(k) clearance from the FDA, and is not available for a full fledged commercial launch in the domestic market.
Over the last three months, the price performance of NxStage Medical has been encouraging. The stock added 17%, comparing favorably with the Zacks classified Medical Products sub-industry’s gain of 12.7%. Also, the current level compares favorably with the S&P 500’s return of 7.8% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been disappointing. The full year has seen two estimates move south over the last one month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year dropped 50% to a penny over the same time frame. Notably, the stock has Zacks Rank #3 (Hold).
Getting back to the latest development, NxGen is expected to enhance the company’s portfolio incorporating new features and capabilities to the existing line of products. In this regard, the NxStage Medical has been gaining prominence in the markets with products like NxStage PureFlow SL Dialysis Preparation System, Nx2me Connected Health and NxStage System One.
We are upbeat on the latest developments in the broader hemodialysis market. Notably, a report by Markets And Markets suggests that the global hemodialysis market is projected to reach a worth of nearly $83.89 billion by 2020, multiplying at a CAGR of 6%, with strong prospects in Europe. Meanwhile, NxStage Medical promises a long-term expected earnings growth rate of 16.3%, instilling confidence in investors.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 184.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 1.23% over the last three months.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NxStage Medical: NxGen Hemodialysis System Now CE Marked
NxStage Medical, Inc. recently announced the receipt of CE mark for its NxGen Hemodialysis System, an innovative device with easier user interface and integrated blood pressure monitor system for patients performing home hemodialysis. This approval is expected to strengthen the company’s foothold in the growing hemodialysis care market in Europe.
Notably, NxGen leverages on the company’s flagship NxStage System One, the first and only portable hemodialysis system, which has been cleared by the US FDA for home hemodialysis and home nocturnal hemodialysis. However, NxGen is currently under the review for a 510(k) clearance from the FDA, and is not available for a full fledged commercial launch in the domestic market.
Over the last three months, the price performance of NxStage Medical has been encouraging. The stock added 17%, comparing favorably with the Zacks classified Medical Products sub-industry’s gain of 12.7%. Also, the current level compares favorably with the S&P 500’s return of 7.8% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been disappointing. The full year has seen two estimates move south over the last one month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year dropped 50% to a penny over the same time frame. Notably, the stock has Zacks Rank #3 (Hold).
Getting back to the latest development, NxGen is expected to enhance the company’s portfolio incorporating new features and capabilities to the existing line of products. In this regard, the NxStage Medical has been gaining prominence in the markets with products like NxStage PureFlow SL Dialysis Preparation System, Nx2me Connected Health and NxStage System One.
NxStage Medical, Inc. Price
NxStage Medical, Inc. Price | NxStage Medical, Inc. Quote
We are upbeat on the latest developments in the broader hemodialysis market. Notably, a report by Markets And Markets suggests that the global hemodialysis market is projected to reach a worth of nearly $83.89 billion by 2020, multiplying at a CAGR of 6%, with strong prospects in Europe. Meanwhile, NxStage Medical promises a long-term expected earnings growth rate of 16.3%, instilling confidence in investors.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, all the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 184.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 1.23% over the last three months.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>